In this article, published in September edition of Pharmafocus, our Advisory Board Members, Pieter Neels and Steffen Thirstrup share their learnings from the webinar organised by the International Alliance for Biological Standardisation (IABS) and the Coalition for Epidemic Preparedness Innovations (CEPI) on the use of platform technologies for vaccine development earlier this year.

In response to the global emergency caused by the SARS-CoV-2 virus, vaccine development was fast-tracked, there are currently close to 300 vaccine candidates for COVID-19 and one third of these are in clinical development.

Traditionally, the timeline for developing vaccines has been slow. Based on the progression of vaccine platform technology, a better understanding of safe, efficacious vaccine design, could result in extensively shortening development programmes.

There is a whole spectrum of vaccine platforms available, different technologies with both advantages and challenges. Read more about current vaccine platform technology and how the rapid response to tackle emerging infectious diseases can be speed up further.

Read More


The Authors


Dr Steffen Thirstrup


Dr Pieter Neels

Advisory Board Member

Read More

Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.